Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederema.europa.eu
What's new
Get the latest updates from What's new directly as they happen.
Follow now 332 followers
Latest posts
Last updated about 11 hours ago
Human medicines European public assessment report (EPAR): Yervoy, ipilimumab, Date of authorisation: 13/07/2011, Revision: 60, Status: Authorised
about 11 hours ago
Human medicines European public assessment report (EPAR): Yervoy, ipilimumab, Date of authorisation...
Outcome of written procedures finalised during the period from 04 March 2026 to 03 June 2026
about 12 hours ago
Outcome of written procedures finalised during the period from 04 March 2026...
Overview of Network Data Steering Group (NDSG) change management activities 2025-2026
about 12 hours ago
Overview of Network Data Steering Group (NDSG) change management activities 2025-2026
Human medicines European public assessment report (EPAR): Dazluma, troriluzole, Status: Application withdrawn
about 12 hours ago
Human medicines European public assessment report (EPAR): Dazluma, troriluzole, Status: Application withdrawn
Breakthrough medical devices: information session, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 April 2026, 15:00 (CEST) to 24 April 2026, 17:00 (CEST)
about 12 hours ago
Breakthrough medical devices: information session, Online, European Medicines Agency, Amsterdam, the Netherlands...
Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation: 23/08/2022, Revision: 8, Status: Authorised
about 12 hours ago
Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation...
Human medicines European public assessment report (EPAR): Privigen, human normal immunoglobulin (IVIg), Date of authorisation: 24/04/2008, Revision: 33, Status: Authorised
about 12 hours ago
Human medicines European public assessment report (EPAR): Privigen, human normal immunoglobulin (IVIg)...
ICH E22 General considerations for patient preference studies - Scientific guideline
about 16 hours ago
ICH E22 General considerations for patient preference studies - Scientific guideline
Appendix 1: Acceptable intakes established for N-nitrosamines
about 16 hours ago
Appendix 1: Acceptable intakes established for N-nitrosamines
Human medicines European public assessment report (EPAR): Evfraxy, denosumab, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised
1 day ago
Human medicines European public assessment report (EPAR): Evfraxy, denosumab, Date of authorisation...